Zoetis (NYSE:ZTS)‘s stock had its “buy” rating reaffirmed by equities research analysts at Jefferies Group in a research note issued to investors on Friday. They presently have a $96.00 target price on the stock. Jefferies Group’s price objective suggests a potential upside of 14.87% from the stock’s previous close. Jefferies Group also issued estimates for Zoetis’ Q1 2018 earnings at $0.71 EPS, FY2018 earnings at $3.07 EPS, FY2019 earnings at $3.56 EPS, FY2020 earnings at $4.11 EPS, FY2021 earnings at $4.56 EPS and FY2022 earnings at $5.09 EPS.
Several other research analysts have also issued reports on the company. Morgan Stanley lowered Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 price target on the stock. in a research report on Monday, March 19th. They noted that the move was a valuation call. Credit Suisse Group lifted their target price on Zoetis from $83.00 to $89.00 and gave the stock an “outperform” rating in a report on Thursday, April 5th. ValuEngine upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Deutsche Bank lifted their target price on Zoetis from $76.00 to $78.00 and gave the stock a “hold” rating in a report on Friday, February 16th. Finally, Barclays set a $77.00 price target on Zoetis and gave the company a “hold” rating in a research note on Saturday, February 17th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $80.89.
Shares of NYSE:ZTS opened at $83.57 on Friday. Zoetis has a twelve month low of $53.00 and a twelve month high of $85.73. The company has a market cap of $40,741.90, a P/E ratio of 34.82, a price-to-earnings-growth ratio of 1.88 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77.
In other Zoetis news, insider Roman Trawicki sold 23,885 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $82.00, for a total transaction of $1,958,570.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Heidi C. Chen sold 37,453 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total transaction of $3,034,442.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,952 shares of company stock worth $9,219,843. Company insiders own 0.35% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ZTS. Chemical Bank bought a new stake in Zoetis during the fourth quarter valued at $350,000. Cambridge Investment Research Advisors Inc. lifted its position in Zoetis by 27.9% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 17,881 shares of the company’s stock valued at $1,288,000 after acquiring an additional 3,904 shares in the last quarter. Xact Kapitalforvaltning AB lifted its position in Zoetis by 9.8% in the 4th quarter. Xact Kapitalforvaltning AB now owns 70,114 shares of the company’s stock valued at $5,051,000 after acquiring an additional 6,253 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Zoetis by 31.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 134,904 shares of the company’s stock valued at $9,719,000 after acquiring an additional 32,149 shares in the last quarter. Finally, Dixon Hubard Feinour & Brown Inc. VA lifted its position in Zoetis by 106.2% in the 4th quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 25,090 shares of the company’s stock valued at $1,807,000 after acquiring an additional 12,925 shares in the last quarter. Institutional investors and hedge funds own 92.44% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.